Navigation Links
Mayo Clinic: Rotavirus vaccine given to newborns in Africa is effective
Date:6/17/2013

ROCHESTER, Minn. -- Mayo Clinic and other researchers have shown that a vaccine given to newborns is at least 60 percent effective against rotavirus in Ghana. Rotavirus causes fever, vomiting and diarrhea, which in infants can cause severe dehydration. In developed nations, the condition often results in an emergency room visit or an occasional hospitalization, but is rarely fatal. In developing countries, however, rotavirus-related illness causes approximately 500,000 deaths per year. The findings appear this week in the Journal of Infectious Diseases.

Currently, there is no neonatal rotavirus vaccine available and infants do not receive their first dose of a rotavirus vaccine until they are approximately 2 months old, leaving younger infants at serious risk of rotavirus infection. In the study, the first of two doses was administered within the first 29 days of life (neonatal dosing), and the second dose before 60 days of age.

"For the first time in a large-scale study, we have demonstrated that protection against rotavirus gastroenteritis can be achieved earlier in life," says co-author and pediatrician Robert M. Jacobson, M.D., of the Mayo Clinic Children's Center. "The next step should be additional studies in neonates to provide earlier protection against life-threatening rotavirus diarrhea. The rotavirus vaccines used in America and Europe are administered later -- when babies are 2 to 4 months old -- but younger infants also contract the virus in the first two months of life."

Two vaccines serve as standard protection in developed countries, but are not especially effective in African or Asian countries, says Dr. Jacobson. Besides, he says, protection is also needed from birth due to the widespread risk of the virus.

"There is a huge protection gap right now in the first months of life," says Dr. Jacobson. "This study points to a clear and practical solution."

In Ghana, 998 newborns were selected for the randomized, double-blind, placebo trial from two of the poorest parts of the country. Half received the oral reassortant rotavirus tetravalent vaccine (RRV-TV) in the first two months of life, half received a placebo. Results showed a significant response in parameters of efficacy, safety and immune impact of the vaccine.


'/>"/>

Contact: Bob Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: How gold nanoparticles can help fight ovarian cancer
2. Mayo Clinic: Inflammatory bowel disease raises risk of melanoma
3. Mayo Clinic: Scheduled imaging studies provide little help detecting relapse of aggressive lymphoma
4. Mayo Clinic: New multiple myeloma treatment guidelines personalize therapy for patients
5. Mayo Clinic: Skin problems, joint disorders top list of reasons people visit doctors
6. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
7. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
8. Mayo Clinic: Antidepressant eases radiation-related mouth pain in head, neck cancer
9. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
10. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
11. Mayo Clinic: Common blood pressure drug linked to severe GI problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... squash, announced it has enlisted New York City-based sports and entertainment marketing firm ... and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ...
(Date:3/29/2017)... MD (PRWEB) , ... March 30, 2017 , ... CHARM ... Charm City Run has announced that Mercy Medical Center will serve as the official ... the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk or ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today ... normally at $29.97; for the remaining days of March, the price will be only ... a special price of just $10 (regular retail price $19.97). , The special promotional ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... services with or without a referral to new patients from Burnaby, BC. Patients ... or other full mouth reconstruction services, can see the esteemed team at Wall ...
(Date:3/29/2017)... Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... patients on early orthodontic treatment and accepting new pediatric patients, with or without a ... help young patients have a better orthodontic outcome and experience. When patients receive early ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... DES MOINES, Iowa , March 29, 2017 ... Iowa Lt. Gov. Kim Reynolds , Department of Public ... Control Policy Director Steve Lukan in announcing the ... at all CVS Pharmacy locations in Iowa.  CVS Health has ... that allows CVS Pharmacy to expand access to ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "South ... & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected to ... Untapped Proton Therapy Market for South Korea was ... Proton Therapy plays an important role in delivering comprehensive cancer care to ...
Breaking Medicine Technology: